12th July 2017 – Munich
Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH(BI) entered a non-exclusive license agreement for cell-based splitSENSOR assays providing BI with the options to screen for selected target activities relevant to schizophrenia.Systasy’s proprietary splitSENSOR assays are applied to assess activities and specificities of drug-able targets, such as receptor tyrosine kinases and G protein-coupled receptors. Through a better understanding of compound-mediated actions on target activation and inhibition at early stages of each screening campaign, the drug development process will be accelerated.
BI aims at generating targets for the treatment of schizophrenia. Schizophrenia is a chronic, severe and disabling mental disorder ranked among the 12 most debilitating diseases by the World Health Organisation. It affects about 1 in 100 people worldwide, changing the way they behave, think and perceive the world. Although anti-psychotic medications and psychosocial interventions can effectively reduce symptoms and improve patients’ lives, there remains a strong need for new drugs and causative mechanisms and cognitive impairment. Boehringer Ingelheim acquired a non-exclusive splitSENSOR license to screen compound libraries of any size for selected targets,
Systasy, a growing start-up company founded in Munich in 2012, provides cost-effective and highly innovative solutions to address critical and unmet needs of the pharmaceutical industry. Systasy’s products and services are ranging from the analysis of cellular target activities and specificities to the simultaneous analysis of multiple pathways in living cells, based on their proprietary splitSENSOR and EXTassay technologies. Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneous cellular events to customers. Thus, Systasy’s services and products are designed to meet customers needs in the early phases of drug discovery and personalised medicine.